TY - JOUR
KW - Analgesics, Opioid/therapeutic use
KW - Australia
KW - Betacoronavirus
KW - Buprenorphine/therapeutic use
KW - COVID-19
KW - Canada
KW - Community Pharmacy Services
KW - Coronavirus Infections
KW - Delivery of Health Care
KW - Health Services Accessibility
KW - Humans
KW - Methadone/therapeutic use
KW - Opiate Substitution Treatment
KW - Opioid-Related Disorders/drug therapy
KW - Pandemics
KW - Pharmacists
KW - Pneumonia, Viral
KW - SARS-CoV-2
KW - scope of practice
KW - United Kingdom
KW - United States
KW - community pharmacy
KW - Medication for opioid use disorder
AU - G. Cochran
AU - J. Bruneau
AU - N. Cox
AU - A. J. Gordon
A1 - 
AB - Medications for opioid use disorder (MOUD), such as methadone and buprenorphine, are effective strategies for treatment of opioid use disorder (OUD) and reducing overdose risk. MOUD treatment rates continue to be low across the US, and currently, some evidence suggests access to evidence-based treatment is becoming increasingly difficult for those with OUD as a result of the 2019 novel corona virus (COVID-19). A major underutilized source to address these serious challenges in the US is community pharmacy given the specialized training of pharmacists, high levels of consumer trust, and general availability for accessing these service settings. Canadian, Australian, and European pharmacists have made important contributions to the treatment and care of those with OUD over the past decades. Unfortunately, US pharmacists are not permitted to prescribe MOUD and are only currently allowed to dispense methadone for the treatment of pain, not OUD. US policymakers, regulators, and practitioners must work to facilitate this advancement of community pharmacy-based through research, education, practice, and industry. Advancing community pharmacy-based MOUD for leading clinical management of OUD and dispensation of treatment medications will afford the US a critical innovation for addressing the opioid epidemic, fallout from COVID-19, and getting individuals the care they need.
AD - Greater Intermountain Node, a NIH NIDA Clinical Trial Network node and Program for Addiction Research, Clinical Care, Knowledge and Advocacy (PARCKA), University of Utah School of Medicine, Department of Internal Medicine, Division of Epidemiology, University of Utah School of Medicine, Salt Lake City, Utah, USA.; Department of family medicine and emergency medicine, Université de Montréal, Montréal, Canada.; Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake City, Utah, USA.; Greater Intermountain Node, a NIH NIDA Clinical Trial Network node and Program for Addiction Research, Clinical Care, Knowledge and Advocacy (PARCKA), University of Utah School of Medicine, Department of Internal Medicine, Division of Epidemiology, University of Utah School of Medicine, Salt Lake City, Utah, USA.; Vulnerable Veteran Innovative PACT (VIP) Initiative; Informatics, Decision-Enhancement, and Analytic Sciences Center (IDEAS Center), VA Salt Lake City Health Care System, Salt Lake City, Utah, USA.
BT - Substance abuse
C5 - Education & Workforce; Healthcare Policy; Opioids & Substance Use
CP - 3
DO - 10.1080/08897077.2020.1787300
IS - 3
JF - Substance abuse
LA - eng
M1 - Journal Article
N2 - Medications for opioid use disorder (MOUD), such as methadone and buprenorphine, are effective strategies for treatment of opioid use disorder (OUD) and reducing overdose risk. MOUD treatment rates continue to be low across the US, and currently, some evidence suggests access to evidence-based treatment is becoming increasingly difficult for those with OUD as a result of the 2019 novel corona virus (COVID-19). A major underutilized source to address these serious challenges in the US is community pharmacy given the specialized training of pharmacists, high levels of consumer trust, and general availability for accessing these service settings. Canadian, Australian, and European pharmacists have made important contributions to the treatment and care of those with OUD over the past decades. Unfortunately, US pharmacists are not permitted to prescribe MOUD and are only currently allowed to dispense methadone for the treatment of pain, not OUD. US policymakers, regulators, and practitioners must work to facilitate this advancement of community pharmacy-based through research, education, practice, and industry. Advancing community pharmacy-based MOUD for leading clinical management of OUD and dispensation of treatment medications will afford the US a critical innovation for addressing the opioid epidemic, fallout from COVID-19, and getting individuals the care they need.
PY - 2020
SN - 1547-0164; 0889-7077; 0889-7077
SP - 269
EP - 274
EP - 
T1 - Medication treatment for opioid use disorder and community pharmacy: Expanding care during a national epidemic and global pandemic
T2 - Substance abuse
TI - Medication treatment for opioid use disorder and community pharmacy: Expanding care during a national epidemic and global pandemic
U1 - Education & Workforce; Healthcare Policy; Opioids & Substance Use
U2 - 32697171
U3 - 10.1080/08897077.2020.1787300
VL - 41
VO - 1547-0164; 0889-7077; 0889-7077
Y1 - 2020
ER -